ReviewCurrent hematologic malignancy reports2019
Targeting the JAK/STAT Pathway in T Cell Lymphoproliferative Disorders.
Review in Current hematologic malignancy reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Non-receptor tyrosine kinase signaling pathways and therapeutic implications.Signal transduction and targeted therapy · 2026Review
- Real-world efficacy and safety of golidocitinib in 3 patients with relapsed/refractory peripheral T-cell lymphoma.Frontiers in oncology · 2026Article
- Inflammation as a driver of hematological malignancies.Frontiers in oncology · 2024Review
- Extranodal T- and NK-cell lymphomas.Virchows Archiv : an international journal of pathology · 2023Review
- Multiomics to investigate the mechanisms contributing to repression of PTPRC and SOCS2 in pediatric T-ALL: Focus on miR-363-3p and promoter methylation.Genes, chromosomes & cancer · 2022Article
- JAK/STAT Signaling: Molecular Targets, Therapeutic Opportunities, and Limitations of Targeted Inhibitions in Solid Malignancies.Frontiers in pharmacology · 2022Review
- Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors-A Strategy for Hematological Malignancies?Cancers · 2021Review
- T-cell and NK-cell neoplasms of the gastrointestinal tract - recurrent themes, but clinical and biological distinctions exist.Haematologica · 2020Article
- Therapeutic targeting of JAKs: from hematology to rheumatology and from the first to the second generation of JAK inhibitors.Mediterranean journal of rheumatology · 2020Review
- The Role of IL-35 in the Pathophysiological Processes of Liver Disease.Frontiers in pharmacology · 2020Review
- A Network Pharmacology Approach to Explore the Mechanisms of Shugan Jianpi Formula in Liver Fibrosis.Evidence-based complementary and alternative medicine : eCAM · 2020Article
- Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewT cell lymphoproliferative disorders represent a diverse group of hematologic malignancies with poor prognosis underscoring the need for novel therapeutic approaches. Disruption of the JAK/STAT signaling pathway has been described in this group of blood cancers and may represent an approach for targeted therapy. Here, we summarize the current data describing the disruptions of JAK/STAT signaling in T cell malignancies and focus on the existing evidence for exploitation of this pathway with targeted therapies. RECENT
findingsTo date, preclinical studies have demonstrated the efficacy of JAK/STAT inhibition in the treatment of several T cell lymphoproliferative disorders. More recently, several early clinical trials have demonstrated promising results utilizing this approach as well. The benefit of the combination of JAK/STAT-targeted therapies along with immunotherapy and other molecularly targeted therapies is also discussed. There is substantial evidence that targeting the JAK/STAT pathway in T cell lymphoproliferative disorders could be of clinical benefit. There are several early clinical trials showing promise and many ongoing trials investigating the optimal utility of agents that inhibit this signaling pathway. In addition, targeting this pathway may provide a platform for further rational combination therapies.
Indexed as
Identifiers
31741284What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.